CY1111530T1 - Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις - Google Patents

Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις

Info

Publication number
CY1111530T1
CY1111530T1 CY20111100192T CY111100192T CY1111530T1 CY 1111530 T1 CY1111530 T1 CY 1111530T1 CY 20111100192 T CY20111100192 T CY 20111100192T CY 111100192 T CY111100192 T CY 111100192T CY 1111530 T1 CY1111530 T1 CY 1111530T1
Authority
CY
Cyprus
Prior art keywords
ethyl
phenolate
dimethylamine
propyl
methyl
Prior art date
Application number
CY20111100192T
Other languages
English (en)
Inventor
Andreas Fischer
Helmut Buschmann
Michael Gruss
Dagmar Lischke
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111530(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1111530T1 publication Critical patent/CY1111530T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η εφεύρεση αυτή αφορά μία νέα κρυσταλλική μορφή υδροχλωριδίου (-)-(1R,2R)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινόλης, μεθόδους για την παρασκευή της, μεθόδους για τη χρήση της και φαρμακευτικές συνθέσεις που την περιέχουν.
CY20111100192T 2004-06-28 2011-02-16 Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις CY1111530T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
EP05770026A EP1799633B1 (en) 2004-06-28 2005-06-27 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride for use as active ingredient in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY1111530T1 true CY1111530T1 (el) 2015-08-05

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101312T CY1106929T1 (el) 2004-06-28 2007-10-11 Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
CY20111100192T CY1111530T1 (el) 2004-06-28 2011-02-16 Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071101312T CY1106929T1 (el) 2004-06-28 2007-10-11 Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης

Country Status (27)

Country Link
US (16) US20070213405A1 (el)
EP (2) EP1612203B1 (el)
JP (1) JP4990764B2 (el)
KR (1) KR101096501B1 (el)
CN (1) CN1997621B (el)
AR (2) AR049949A1 (el)
AT (2) ATE368639T1 (el)
AU (1) AU2005256512B2 (el)
BR (2) BRPI0512792A (el)
CA (1) CA2572147C (el)
CY (2) CY1106929T1 (el)
DE (2) DE602004007905T2 (el)
DK (2) DK1612203T3 (el)
EC (1) ECSP17046065A (el)
ES (2) ES2291780T3 (el)
HR (1) HRP20110050T8 (el)
IL (1) IL180373A (el)
MX (1) MXPA06014741A (el)
NO (3) NO338605B1 (el)
NZ (1) NZ551605A (el)
PE (1) PE20060372A1 (el)
PL (2) PL1612203T3 (el)
PT (2) PT1612203E (el)
RU (1) RU2423345C2 (el)
SI (2) SI1612203T1 (el)
WO (1) WO2006000441A2 (el)
ZA (1) ZA200700774B (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602004007905T2 (de) * 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
CN104447361B (zh) 2007-12-07 2017-04-12 格吕伦塔尔有限公司 (1r,2r)‑3‑(3‑二甲基氨基‑1‑乙基‑2‑甲基‑丙基)‑苯酚的结晶变体
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
AU2010275755B2 (en) 2009-07-22 2014-04-24 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
EP3636629A1 (en) 2010-07-23 2020-04-15 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
EA024193B1 (ru) * 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
DK2680832T3 (da) 2011-03-04 2019-10-14 Gruenenthal Gmbh Vandig farmaceutisk formulering af tapentadol til oral administration
HUE034710T2 (hu) 2011-07-29 2018-02-28 Gruenenthal Gmbh Visszaéléssel szemben ellenálló, azonnali hatóanyagfelszabadulást biztosító tabletta
PT2736495T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017018569A2 (pt) 2015-03-27 2018-04-24 Gruenenthal Gmbh formulação estável para administração parentérica de tapentadol
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
PL3819287T3 (pl) 2016-04-19 2024-03-11 Ratiopharm Gmbh Amorficzny fosforan tapentadolu
EA201990744A1 (ru) 2016-09-23 2019-08-30 Грюненталь Гмбх Стабильная лекарственная форма для парентерального введения тапентадола
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2022098644A1 (en) 2020-11-03 2022-05-12 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PL191313B1 (pl) * 1996-08-14 2006-04-28 Searle & Co Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania
WO2002036542A1 (en) * 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
MXPA04002449A (es) * 2001-09-13 2004-07-23 Kissei Pharmaceutical Cristales de derivado de hidroxinorefedrina.
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE602004007905T2 (de) * 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid

Also Published As

Publication number Publication date
NO20171103A1 (no) 2007-01-24
RU2423345C2 (ru) 2011-07-10
ECSP17046065A (es) 2018-11-30
US20180029976A1 (en) 2018-02-01
ATE368639T1 (de) 2007-08-15
WO2006000441A3 (en) 2006-05-04
CA2572147C (en) 2012-10-30
US20230174458A1 (en) 2023-06-08
DK1799633T3 (da) 2011-03-28
US20200385334A1 (en) 2020-12-10
US20090186947A1 (en) 2009-07-23
HRP20110050T8 (en) 2011-03-31
US20210261492A1 (en) 2021-08-26
US20190062263A1 (en) 2019-02-28
PT1612203E (pt) 2007-08-20
RU2007103297A (ru) 2008-08-10
ES2359504T3 (es) 2011-05-24
BR122018014454B1 (pt) 2019-09-03
CN1997621B (zh) 2011-06-15
US20140296346A1 (en) 2014-10-02
WO2006000441A2 (en) 2006-01-05
HRP20110050T1 (hr) 2011-02-28
US20100160447A1 (en) 2010-06-24
DE602005026031D1 (de) 2011-03-03
US20110294898A1 (en) 2011-12-01
EP1799633B1 (en) 2011-01-19
AU2005256512A1 (en) 2006-01-05
KR101096501B1 (ko) 2011-12-20
BRPI0512792A (pt) 2008-04-08
NO20070162L (no) 2007-01-24
NZ551605A (en) 2010-01-29
PT1799633E (pt) 2011-03-07
BR122018014454B8 (pt) 2021-07-27
US20180230082A1 (en) 2018-08-16
MXPA06014741A (es) 2007-02-12
NO20160914A1 (no) 2007-01-24
DE602004007905T2 (de) 2008-05-08
EP1612203A1 (en) 2006-01-04
CN1997621A (zh) 2007-07-11
DK1612203T3 (da) 2007-12-03
SI1612203T1 (sl) 2007-12-31
EP1799633A2 (en) 2007-06-27
US20070213405A1 (en) 2007-09-13
KR20070039929A (ko) 2007-04-13
CA2572147A1 (en) 2006-01-05
ZA200700774B (en) 2008-09-25
NO338605B1 (no) 2016-09-12
US20200102261A1 (en) 2020-04-02
NO341239B1 (no) 2017-09-25
ES2291780T3 (es) 2008-03-01
US7994364B2 (en) 2011-08-09
AR049949A1 (es) 2006-09-20
AU2005256512B2 (en) 2011-05-19
US20120302643A1 (en) 2012-11-29
PL1799633T3 (pl) 2011-06-30
SI1799633T1 (sl) 2011-05-31
US20160122287A1 (en) 2016-05-05
PL1612203T3 (pl) 2007-12-31
IL180373A0 (en) 2007-06-03
DE602004007905D1 (de) 2007-09-13
AR116052A2 (es) 2021-03-25
US20140011886A1 (en) 2014-01-09
JP4990764B2 (ja) 2012-08-01
PE20060372A1 (es) 2006-05-08
EP1612203B1 (en) 2007-08-01
US20170166515A1 (en) 2017-06-15
CY1106929T1 (el) 2012-09-26
ATE496021T1 (de) 2011-02-15
NO343922B1 (no) 2019-07-08
JP2008504326A (ja) 2008-02-14
IL180373A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
CY1111530T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης για τη χρηση σαν ενεργο συστατικο σε φαρμακευτικες συνθεσεις
CY1124873T1 (el) Διεργασια για την παρασκευη (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
ATE528989T1 (de) Kristalline feste rasagilin-base
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
ATE515491T1 (de) Herstellung von 3-ä(1r,2r)-3-(dimethylamino)- 1ethyl-2-methylpropylüphenol
EA200501563A1 (ru) Пролекарства ингибиторов киназы pi-3
BRPI0606118A2 (pt) uma sìntese assimétrica de (s) - (+) -3- (aminometil) -5- ácido metilhexanóico
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
DK2407451T3 (da) N,N-substituerede 3-aminopyrrolidin-forbindelser anvendelige som monoamin-genoptagelseshæmmere
EA200801414A1 (ru) Кальцилитические соединения
EA200801199A1 (ru) Ингибиторы киназы
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CY1113533T1 (el) Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης
EA200602017A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
CL2011001590A1 (es) Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion.
EA200970167A1 (ru) Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина
EA200601402A1 (ru) L-(+)-тартрат l-(-)- мопролола
TH150590A (th) เกลือเบซิเลต (Besylate salt) ของสารยับยั้ง BTK
CY1115454T1 (el) Παραγωγα πυριδιζινονης
DOP2004000916A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoaminas